Results 81 to 90 of about 3,887,212 (164)

A case report of enduring benefit of sequential PRRT in malignant insulinoma

EJNMMI Reports
We report the case of a 62-year-old woman diagnosed in 2015 with de novo metastatic malignant insulinoma. She presented severe hypoglycemia and was initially treated with somatostatin analogs, chemotherapy (capecitabine-temozolomide), and diazoxide, but ...
Cristina-An Wang Zhang, Natacha Driessens, Magdalena Mileva, Amélie Deleporte, Patrick Flamen, Ioannis Karfis   +5 more
doaj   +1 more source

Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT

Endocrine Oncology
There is interest in optimizing peptide receptor radionuclide therapy (PRRT) for the management of metastatic neuroendocrine neoplasms (NEN). The addition of stereotactic body radiation therapy (SBRT) may provide synergistic benefits by targeting ...
Jose E Nunez, Sylvia Ng, Hanbo Chen, Simron Singh, Julie Hallet, Calvin Law, Sten Myrehaug   +6 more
doaj   +1 more source

Efficacy of ¹⁷⁷Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study

Current Oncology, 2020
Peptide receptor radionuclide therapy (PRRT) has been recently established as a treatment option for progressive gastro-entero-pancreatic neuroendocrine tumors (NETs) including four 200 mCi induction cycles. The purpose of this phase 2 trial is to expand
Golmehr Sistani, Duncan E. K. Sutherland, Amol Mujoomdar, Daniele P. Wiseman, Alireza Khatami, Elena Tsvetkova, Robert H. Reid, David T. Laidley   +7 more
doaj   +1 more source

A Biochemically “Silent” Aortocaval Paraganglioma in a 19‐Year‐Old Female Causing Intraoperative Hypertensive Crisis: A Rare Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Paragangliomas may appear biochemically silent, yet still behave as functional tumors with severe intraoperative consequences. Normal preoperative catecholamine screening does not exclude the risk of hypertensive crisis during surgery.
Abdul Basit, Tooba Yaqoob, Eyman Farrukh, Abdullah Iftikhar, Muhammad Usman Ali Khan, Majeed Haq   +5 more
wiley   +1 more source

Improving the quality of care delivery during Peptide Receptor Radionuclide Therapy (PRRT) for patients with Neuroendocrine Neoplasms (NENs): Development and implementation of personalised patient planners (PPS) to streamline complex multidisciplinary care

, 2020
Peptide Receptor Radionuclide Therapy (PRRT) is a complex treatment modality for patients and their carers to navigate alone. As PRRT is a tertiary/quaternary service, patients are often referred from smaller institutions with potential for confusion due
Corsini, Nadia, Chan, Bryan, Mercurio, Jessica, Eckert, Marion, Cummins, Meredith, Altus, Liesl, Cehic, Gabrielle   +6 more
core   +1 more source

Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Challenge and Case Report

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Primary neuroendocrine carcinoma of the breast (NECB) represents an exceedingly rare entity, comprising less than 0.5% of all breast carcinomas and approximately 1% of all neuroendocrine neoplasms. The 2019 WHO classification defines NECB as tumors expressing neuroendocrine markers in > 90% of tumor cells with morphological features
Hamid Zeinali Nezhad, Shima Yaghoobi, Nazanin Zeinali Nezhad, Amirhossein Shahpar, Abtin Malekpour Afshar, Mina Bagherijamebozorgi   +5 more
wiley   +1 more source

Theranostics in Pancreatic Neuroendocrine Neoplasms: From Molecular Imaging to Personalized Radionuclide Therapy

Radiation
Pancreatic neuroendocrine neoplasms (PanNENs) are a heterogeneous group of tumors characterized by variable biological behavior and frequent overexpression of somatostatin receptors, making them ideal candidates for theranostic approaches.
Takehiro Okabayashi, Ryo Inada, Motoyasu Tabuchi, Rika Yoshimatsu, Yuji Negoro, Akihito Nishioka   +5 more
doaj   +1 more source

Advanced Peptide Receptor Radionuclide Therapy to Overcome Refractory Hypoglycemic Insulinoma: A Case Report and Review of the Literature

Journal of Medical Sciences
We reported the case of a 42-year-old man with refractory hypoglycemia caused by an inoperable malignant insulinoma and multiple liver metastases. The patient initially received bi-weekly intramuscular injections of octreotide long-acting release and a ...
Yi-Hsiang Huang, Sheng-Chiang Su, Tzu-Chuan Huang   +2 more
doaj   +1 more source

Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres

Current Oncology
Pancreatic neuroendocrine tumors (pNETs) are rare but increasingly prevalent malignancies with varied prognoses and a diverse range of treatment options, including surgery, somatostatin analogues (SSAs), chemotherapy, targeted therapy, and peptide ...
Gautham Nair, Morgan Black, Kathie Baer, Stephen Welch, David T. Laidley, Rachel Goodwin, Macyn Leung, William J. Phillips, Michael Vickers, Tim Asmis, Horia Marginean, Elena Tsvetkova   +11 more
doaj   +1 more source

Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report

Surgical Case Reports
Background Peptide receptor radionuclide therapy (PRRT) serves as a novel and effective treatment option for somatostatin receptor-positive unresectable liver metastases of pancreatic neuroendocrine tumors (PNETs).
Ryosuke Umino, Satoshi Nara, Noritoshi Kobayashi, Takahiro Mizui, Takeshi Takamoto, Daisuke Ban, Minoru Esaki, Nobuyoshi Hiraoka, Kazuaki Shimada   +8 more
doaj   +1 more source